City of Hope | Strategic Alliance Partners

An expert panel reviews recent updates on BCMA-targeting bispecific antibodies in multiple myeloma.

Krina Patel, MD, reviews data from the CARTITUDE-4 and KarMMa-3 studies and shares perspectives on a potential role for CAR T-cell therapy at early relapse.

Focus on methods for preventing graft-versus-host disease (GvHD) following allo-HSCT, such as pharmacologic immune suppression and stem cell graft manipulation techniques.

Summarize ongoing and recently completed clinical trials related to allo-HSCT and associated therapies.

Ibrahim T. Aldoss, MD, discusses the use of revumenib monotherapy in patients with relapsed/refractory acute leukemia harboring KMT2A rearrangements.

The absence of clearly articulated definitions and transparency related to how clinical trial outcomes are interpreted and utilized raise concerns.

A panel of expert hematologic-oncologists offer insights on how they treat patients with multiple myeloma at early relapse.

The expert panel discusses how the standard of care for transplant-ineligible NDMM has evolved and reviews recent updates in this space.

Laleh Melstrom, MD, MS, discusses using molecular testing to guide treatment selection for patient with gastrointestinal cancers.

Afsaneh Barzi, MD, PhD, discusses the frontline use of FOLFOXIRI plus bevacizumab and subsequent therapies in patients with metastatic colorectal cancer.

Analyze risks and complications associated with allo-HSCT, including graft-versus-host disease, infections, relapse, and regimen-related toxicities.

This presentation will detail the supportive therapies and interventions provided to patients before, during, and after undergoing allo-HSCT. The speaker will also discuss management of treatment side effects and comorbidities to optimize patient outcomes.

Delve into the pre-transplant conditioning regimens such as chemotherapy and radiation used to prepare and immunosuppress patients to prevent graft rejection prior to allogeneic hematopoietic stem cell transplantation.

Tycel Phillips, MD, discusses the potential advantages of treating patients with relapsed/refractory mantle cell lymphoma in the phase 3 GLOBRYTE trial.

Sumanta Kumar Pal, MD, FASCO, discusses the rationale for treating patients with zanzalintinib in relapsed/refractory clear cell renal cell carcinoma.

Amrita Krishnan, MD, and Saad Z. Usmani, MD, MBA, FACP, offer their perspectives on the role of stem cell transplant and MRD testing in patients with newly diagnosed multiple myeloma.

Clinical insights on the definition of high-risk multiple myeloma and the treatment of patients with high risk disease, including how the results from the IsKia trial might impact practice.

Experts in multiple myeloma discuss highlights from the ASH 2023 meeting around transplant-eligible NDMM with particular focus on the PERSEUS and GRIFFIN trials and the clinical implications of the results of these studies.

Tycel Phillips, MD, discusses the rationale for the phase 3 GLOBRYTE trial examining glofitamab in patients with relapsed/refractory mantle cell lymphoma.

Alexey Danilov, MD, PhD, discusses how further research may address unmet needs in chronic lymphocytic leukemia or mantle cell lymphoma.

Dedication to his patients and the field of hematology spanning decades has led Stephen J. Forman, MD, to break down barriers for treating patients with leukemia and lymphoma.

Maurie Markman, MD, highlights inroads made with immunotherapy, antibody-dependent cytotoxic agents, and molecular testing across oncology.

In this final episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, discuss a roadmap of artificial intelligence (AI) advances in the next 5 to 10 years.

Elizabeth Budde, MD, PhD, presents data from the 3-year follow-up from a pivotal phase II study investigating mosunetuzumab monotherapy in patients with relapsed and/or refractory follicular lymphoma after ≥2 prior therapies.

Elizabeth Budde, MD, PhD, presents data from on mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma.

Drs Simeone and Fakih discuss the main objective and design of the observational BASECAMP-1 study and how it functions alongside the EVEREST-1 study, which is evaluating the autologous CAR T-cell therapy A2B530 in patients with CEA-expressing solid tumors that have lost HLA-A*02 expression.

In this eighth episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, explain how artificial intelligence tools are being developed to match the right patient to the right drug on the right clinical trial.

Experts discuss what role allogeneic transplants play in hematologic malignancies, specifically in AML and ALL.

A panel of experts discuss the evolving landscape of newly diagnosed multiple myeloma.

Revumenib demonstrated clinically meaningful activity, including high response and minimal residual disease negativity rates, in heavily pretreated patients with KMT2A-rearranged acute leukemia.